PLANO, Texas, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced participation in the upcoming Piper Sandler 35th Annual Healthcare Conference to be held in New York City from Nov. 28–30, 2023.
Joseph Dziedzic, President and Chief Executive Officer, is scheduled to present on Wednesday, Nov. 29, 2023, at 10:00 a.m. EST. The presentation will be accessible via a live webcast.
The link to the live webcast may also be accessed under “News & Events” on the Investor Relations section of the Integer website at investor.integer.net. A replay of the webcast will be available on the company’s website for approximately three months.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. Integer provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the Company develops batteries for high-end niche applications in energy, military, and environmental markets. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.
| Investor Relations: | Media Relations: |
| Andrew Senn | Kelly Butler |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| 763.951.8312 | 214.618.4216 |
| Last Trade: | US$116.41 |
| Daily Change: | 0.20 0.17 |
| Daily Volume: | 186,122 |
| Market Cap: | US$3.900B |
March 18, 2025 March 12, 2025 February 20, 2025 February 18, 2025 February 03, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
